Hazlet, NJ, November 30, 2016 --(PR.com
)-- MedLogiq brings technology to the medical device industry that has been a cornerstone of testing and monitoring in the automotive and aviation industries for decades. It will be integrated with the GIP research project developed by the PRECISE Center at the University of Pennsylvania for the Food and Drug Administration to create a Generic Infusion Pump (GIP) “reference” model that improves device safety. There is extensive evidence that identifies an unacceptable rate of safety problems and adverse events from these devices.
By providing technology with demonstrated success; MedLogiq will rapidly enable safety monitoring, performance testing and event data recording capabilities. This is sorely lacking from infusion and other types of medical devices and will deliver benefits across the entire product life cycle. The FDA would receive the necessary data to effectively evaluate and new devices and monitor the performance of the devices in use. Medical device manufacturers will improve safety and performance while decreasing time-to-market. Defects will also be resolved more quickly and cost effectively. User facilities will be able to maintain devices and report adverse events more efficiently. William Acevedo, CEO of MedLogiq stated, “We believe our technology will help close the massive technology gap between medical devices and more advanced industries where it consistently delivers value to all stakeholders throughout the product lifecycle.”
By combining their expertise in communication and data acquisition with advanced technologies from global market leaders like Mahle; MedLogiq vastly improves the safety of medical devices that patients depend on by providing device manufacturers, regulators and user facilities with the tools to maximize data value now and in the future.